Similarly, in the HERACLES study, a phase II trial of trastuzumab and lepatinib in HER-2 positive metastatic CRC, researchers were able to correctly identify the HER-2 amplifications in 96% of samples using ctDNA (10). The gene discussed is ERBB2; the disease is colorectal carcinoma.